Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Published:2019-04-23 Issue:1 Volume:19 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Guo Longhua,Chen Zhihong,Xu Chongrui,Zhang Xuchao,Yan Honghong,Su Jian,Yang Jinji,Xie Zhi,Guo Weibang,Li Feng,Wu Yilong,Zhou Qing

Funder

National Key R&D Program of China

National Natural Science Foundation of China

Special Fund for Research in the Public Interest from National Health and Family Planning Commission of PRC

Natural Science Foundation of Guangdong Province

Research Fund from Guangzhou Science and Technology Bureau

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-019-5555-y.pdf

Reference33 articles.

1. Early-stage lung cancer: trial compares radiosurgery to standard surgery. Oncology 2012, 26(11):1072–1073.

2. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.

3. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology. 2010;11(2):121–8.

4. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.

5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Receptor-Targeted Nanomedicine for Cancer Therapy;Receptors;2024-07-03

2. A Novel Dual-labeled Peptide for Multimodal Imaging of EGFR with L858R Mutation;Current Radiopharmaceuticals;2023-10-17

3. Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib;Lung Cancer: Targets and Therapy;2023-10

4. Deep learning for preoperative prediction of the EGFR mutation and subtypes based on the MRI image of spinal metastasis from primary NSCLC;Biomedical Signal Processing and Control;2023-01

5. Heterogeneous distribution of EGFR mutation in NSCLC: Case report;Respiratory Medicine Case Reports;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3